Challenges in handling allogeneic stem cell transplantation in randomized clinical trials
There is no consensus on handling allo-HSCT as an intercurrent event in survival analyses. Censoring, although common, may introduce bias if treatment or prognostic covariates influence allo-HSCT use. The treatment policy estimand should be preferred when allo-HSCT is part of the therapeutic strategy.
Authors
- Roland Couturier
- Loïc Vasseur (ORCID: https://orcid.org/0000-0001-9065-0477)
- Jérôme Lambert (ORCID: https://orcid.org/0000-0001-7086-9295)
- Nicolas Boissel
- Sylvie Chevret
- Hervé Dombret
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Saint Louis University Hospital (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Paris Cardiovascular Research Center (FR)
- Hôpital Saint-Louis (FR)
Publication Details
- Journal
- Journal of Clinical Epidemiology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1016/j.jclinepi.2026.112132
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00